Skip to main content

Table 3 Univariate analysis of the predictors for failure in clinical resolution (CR)

From: Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii

Variables

With CRa n = 57

Without CRa n = 20

OR (95% CI)

p

Demographic parameters

 Age, year

59.4 (18.9)

63.09 (16.3)

 

0.464

 Female gender

16 (28.1%)

9 (45.0%)

0.48 (0.17–1.37)

0.164

Comorbidities

 Hepatic dysfunction

2 (3.5%)

0 (0.0%)

0.73 (0.64–0.84)

1.000

 Renal insufficiency

6 (10.5%)

1 (5.0%)

2.24 (0.25–19.80)

0.669

 Chronic pulmonary disease

14 (24.6%)

7 (35.0%)

0.60 (0.20–1.82)

0.367

 Heart disease

11 (19.3%)

2 (10.0%)

2.15 (0.43–10.68)

0.495

 Diabetes mellitus

3 (5.3%)

1 (5.0%)

1.06 (0.10–10.77)

1.000

 Immune compromise

3 (5.3%)

2 (10.0%)

0.50 (0.08–3.23)

0.600

 Malignancy

5 (8.8%)

2 (10.0%)

0.86 (0.15–4.86)

1.000

 Hypoproteinemia

1 (1.8%)

1 (5.0%)

0.34 (0.20–5.69)

0.455

 Surgery

11 (19.3%)

5 (25.0%)

0.72 (0.22–2.34)

0.749

Clinical conditions

 CURB65 score, mean ± SD

2.4 (0.6)

1.9 (1.1)

 

0.006

 Mechanical ventilation

31 (64.6%)

17 (85.0%)

0.21 (0.06–0.80)

0.015

 Albumin

31.7 (5.7)

32.2 (4.0)

 

0.512

Microbiology

 Bacteremia

2 (3.5%)

5 (25.0%)

0.11 (0.02–0.62)

0.011

 Tigecycline resistance

33 (57.9%)

9 (45.0%)

1.68 (0.60–4.69)

0.319

 Airway eradication of MDRAB

21 (51.2%)

3 (18.8%)

4.55 (1.13–18.39)

0.026

Tigecycline treatment

 Duration, days

8.4 (3.7)

12.9 (6.4)

 

0.001

Combination therapy

 With sulbactam

49 (86.0%)

15 (75.0%)

2.04 (0.58–7.19)

0.304

 With carbapenems

3 (5.3%)

1 (5.0%)

1.06 (0.10–10.77)

1.000

 With amikacin

2 (3.6%)

1 (5.0%)

0.70 (0.06–8.21)

1.000

 With fluoroquinolones

4 (7.0%)

0 (0.0%)

0.73 (0.63–0.84)

0.568

Delayed tigecycline treatment

19 (33.3%)

2 (10.0%)

4.50 (0.86–13.31)

0.044

  1. Abbreviations: OR odd ratio, CI confidence interval, MDRAB multidrugresistik Acinetobacter baumannii
  2. aCategorical data are no.(%) of subject, continuous data are expressed as mean (standard deviation)